News

Press

Press

Biond Biologics and Guangzhou-Israel Biotechnology Fund (“GIBF”) Announce Closing of $8 Million Investment and Collaboration

הביוטק העולמי נוהר לסין, וחברת סרטן ישראלית מצטרפת למגמה

Biond Biologics Announces Initiation of a Phase 2 Study of BND-22 in Combination with anti-PD-1 therapy

Biond Biologics to Regain Full Rights to BND-22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor

Biond Biologics Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany to Evaluate BND-35 in Combination with Cetuximab in a Phase 1 Clinical Study

October 29, 2024

Biond Biologics Announces First Patient Dosed with BND-35 in Phase 1 Clinical Trial

Biond Biologics Announces Presentation of BND-35, a Novel Anti-ILT3 Antibody for Remodeling the Tumor Microenvironment, at the American Association for Cancer Research (AACR) 2024 Annual Meeting

Biond Biologics Announces a Joint Research Publication With Sanofi in the Journal for ImmunoTherapy of Cancer, “BND-22, a First-In-Class Humanized ILT2-Blocking Antibody, Promotes Antitumor Immunity and Tumor Regression”

September 14, 2022

Biond Biologics Announces a Joint Poster Presentation With Sanofi at The ASCO 2022 Annual Meeting Presenting Pre-Clinical Translational Data of SAR444881 (BND-22)

Biond Biologics Announces First Patients Dosed with BND-22 (SAR444881) Combinations in Phase 1 Clinical Trial